Unity Biotechnology vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Positive 48-week Phase 2 BEHOLD data for UBX1325 in DME published in NEJM Evidence. Single-injection senolytic durability confirmed in diabetic macular edema.
About
Unity Biotechnology is the most clinically advanced senolytic drug company, with its UBX1325 program delivering long-lasting vision improvements in diabetic macular edema (DME) from a single intravitreal senolytic injection. The 48-week Phase 2 BEHOLD trial data published in NEJM Evidence (one of the highest-impact medical journals) confirmed durable efficacy — maintained vision improvement with a single injection over nearly a year — validating the senolytic hypothesis in human ocular disease.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.